Abstract:Novel immunotherapies and small molecular inhibitors are transforming our approach to previously treated and newly diagnosed patients across the spectrum of non-Hodgkin lymphomas (NHLs). Anti-CD19 CAR T cells are now indicated for the treatment of relapsed/refractory aggressive B-cell lymphomas after at least two previous lines of therapy in which durable remissions are achieved in approximately 40% of previously incurable patients. Second-line chemoimmunotherapy remains the standard of care at first relapse, but poor outcomes with conventional treatment in this setting creates an appealing rationale for earlier use of CAR T cells, which is currently under investigation, along with even earlier use in selected high-risk patients in the frontline setting. Other emerging immunotherapies include antibody-drug conjugates (ADCs), such as polatuzumab vedotin for multiple-relapsed diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine-rituximab. Multiple bispecific antibodies that bring malignant B cells in contact with effector T cells appear promising in early clinical trials and will likely emerge as off-the-shelf immunotherapy options. Chemotherapy-free small molecule-based regimens are increasingly available for mantle cell (MCLs) and follicular lymphomas (FLs). Bruton tyrosine kinase inhibitors (BTKi) now represent standard second-line therapy for MCL and are being investigated in combination and as initial therapy. Lenalidomide-rituximab is an active regimen in both FL and MCL and may be used in either relapsed/refractory or previously untreated disease. Three PI3K inhibitors are approved for multiple-relapsed FL and can induce durable remissions in patients with chemotherapy- and rituximab-refractory disease. Additional emerging targeted therapies include BCL2 inhibition in MCL and EZH2 inhibition in FL.

Current status of Bexxar for treatment of non-Hodgkin's lymphoma

Radioligand Therapy in Lymphoma: Past, Present, and Future

Targeting the CD47-SIRPα Signaling Axis: Current Studies on B-cell Lymphoma Immunotherapy

Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives

Bispecific antibodies in indolent B-cell lymphomas

CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas

Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma

[Lymphomas: A therapeutic update]

Perspective on B-cell lymphoma treatment

ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma

Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma

Bexarotene in the treatment of cutaneous T-cell lymphoma

Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma

Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns and opportunities

Recent advances and future perspectives of T-cell engagers in lymphoid malignancies

Taking a BiTE out of Lymphoma: Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma

[T-cell recruiting immunotherapies in B-cell lymphoma - the future backbone for all therapy lines?]

Current salvage therapies in Hodgkin lymphoma

Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting

Effect of 67Cu-2It-bat-lym-1 Therapy on BCL-2 Gene and Protein Expression in a Lymphoma Mouse Model.

Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas